A study led by Griffith University's National Centre for Neuroimmunology and Emerging Diseases (NCNED) has identified a consistent malfunction in the TRPM3 ion channel in immune cells of individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). This discovery provides biological evidence supporting the experiences of ME/CFS patients.
The research team, headed by Professor Sonya Marshall-Gradisnik, found that the TRPM3 ion channel, which is important for calcium transport and cellular regulation, was not functioning properly in immune cells from ME/CFS patients. According to Professor Marshall-Gradisnik, "the TRPM3 played an essential role in calcium transport into cells, regulating responses properly in the body, immune function, and maintaining normal cellular balance."
The study used a gold-standard method to compare TRPM3 activity between ME/CFS patients and healthy controls. The results showed a significant reduction in TRPM3 activity among those with ME/CFS. The findings were reproduced across two independent laboratories separated by more than 4,000 kilometres, highlighting the reliability of the results.
Lead author Dr Etianne Sasso said this work adds to international efforts to understand ME/CFS. She stated: "These results provide further evidence for developing a diagnostic test for ME/CFS, and will also guide us toward new therapeutic targets, which could eventually lead to treatments which improve cellular function and overall quality of life for patients." Dr Sasso noted that people with ME/CFS have long faced skepticism about their condition: "The faulty ion channels act like 'stuck doors', preventing cells from receiving the calcium they need."
Dr Peter Smith, who treats ME/CFS patients, commented on the importance of these findings: "This research provides concrete biological evidence that supports what patients have been describing for decades," he said. "Knowing there is a measurable cellular dysfunction helps us recognise ME/CFS as a legitimate medical condition and improves confidence in patient care. This breakthrough brings real hope for future treatment options."
ME/CFS is characterized by symptoms such as persistent exhaustion, post-exertional malaise, pain, cognitive issues, dizziness, temperature instability and sensory sensitivity. These symptoms can severely limit daily activities.
Participants in the study were recruited from several regions including South East Queensland, North East New South Wales and Western Australia. The research received funding from both the National Health and Medical Research Council of Australia and the Stafford Fox Medical Research Foundation.
